ALX Oncology Appoints Allison Dillon as Chief Business Officer
May 07, 2024 09:00 ET
|
ALX Oncology
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block...
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 07, 2024 07:01 ET
|
Prelude Therapeutics, Inc.
First-in-class IV SMARCA2 degrader, PRT3789 and potentially best-in-class CDK9 inhibitor, PRT2527 remain on track to generate initial proof-of-concept data in 2024 New preclinical data presented at...
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 07, 2024 07:00 ET
|
Arvinas Inc.
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study...
[Latest] Global Breast Cancer Therapeutics Market Size/Share Worth USD 66.1 Billion by 2033 at a 6.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
May 06, 2024 08:30 ET
|
Custom Market Insights
Austin, TX, USA, May 06, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Breast Cancer Therapeutics Market Size, Trends and Insights By Type of Therapy...
BioNTech veröffentlicht Ergebnisse für das erste Quartal 2024 sowie Informationen zur Geschäftsentwicklung
May 06, 2024 06:45 ET
|
BioNTech SE
BioNTech ist auf einem gutem Weg, das Jahresziel von zehn oder mehr potenziell zulassungsrelevanten Studien in der Pipeline bis Ende 2024 zu erreichen: weitere Phase-3-Studie mit der Behandlung der...
BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
May 06, 2024 06:45 ET
|
BioNTech SE
Advancing toward goal of ten or more potentially registrational trials running by the end of 2024: first patient dosed in Phase 3 clinical trial evaluating BNT323/DB-1303 in HR+ HER2-low...
Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
May 02, 2024 16:05 ET
|
Relay Therapeutics, Inc.
Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
Inflammatory Bowel Disease Market To Exhibit Significant Growth by 2032, Predicts DelveInsight | Key Companies Developing Therapies - Arena Pharmaceuticals, Pfizer, Abivax, Janssen, Celgene, Eli Lilly and Company, Merck Sharp & Dohme LLC, T
May 02, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, May 02, 2024 (GLOBE NEWSWIRE) -- Inflammatory Bowel Disease Market To Exhibit Significant Growth by 2032, Predicts DelveInsight | Key Companies Developing Therapies - Arena...
Shape Therapeutics Announces Appointment of Matt Valentino as Chief People Officer
May 02, 2024 08:00 ET
|
Shape Therapeutics, Inc.
SEATTLE, May 02, 2024 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a leader at the convergence of AI and RNA editing to revolutionize genomic medicine, is pleased to announce the...
Muscular Dystrophy Association Launches ALS Awareness Month with Public Service Announcement ‘Answering the Call’
April 29, 2024 09:00 ET
|
Muscular Dystrophy Association
New York, April 29, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced programming and fundraising events in support of people living with Amyotrophic Lateral...